These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 2286714)

  • 1. Neuroleptic malignant syndrome without neuroleptics.
    Parsa MA; Rohr T; Ramirez LF; Meltzer HY
    J Clin Psychopharmacol; 1990 Dec; 10(6):437-8. PubMed ID: 2286714
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuroleptic malignant syndrome without neuroleptics.
    Ong KC; Chew EL; Ong YY
    Singapore Med J; 2001 Feb; 42(2):85-8. PubMed ID: 11358199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.
    Bonnici A; Ruiner CE; St-Laurent L; Hornstein D
    Ann Pharmacother; 2010 Sep; 44(9):1504-7. PubMed ID: 20628041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levodopa-associated hemifacial dystonia.
    Mark MH; Sage JI
    Mov Disord; 1991; 6(4):383. PubMed ID: 1758464
    [No Abstract]   [Full Text] [Related]  

  • 5. A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal.
    Friedman JH; Feinberg SS; Feldman RG
    JAMA; 1985 Nov; 254(19):2792-5. PubMed ID: 4057489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroleptic malignant syndrome associated with the use of carbidopa/levodopa for dystonia in persons with cerebral palsy.
    Perry D; Birthi P; Salles S; McDowell S
    PM R; 2012 May; 4(5):383-4. PubMed ID: 22613365
    [No Abstract]   [Full Text] [Related]  

  • 7. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of drug-induced psychosis in Parkinson's disease with clozapine.
    Greene P; Cote L; Fahn S
    Adv Neurol; 1993; 60():703-6. PubMed ID: 8420214
    [No Abstract]   [Full Text] [Related]  

  • 9. Neuroleptic malignant syndrome. When levodopa withdrawal is the cause.
    Rainer C; Scheinost NA; Lefeber EJ
    Postgrad Med; 1991 Apr; 89(5):175-8, 180. PubMed ID: 2008397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Neuroleptic malignant-like syndrome following levodopa withdrawal].
    Rascol O; Salachas F; Montastruc JL
    Rev Neurol (Paris); 1990; 146(3):215-8. PubMed ID: 2184486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What to do when Sinemet fails: Part one.
    Klawans HL
    Clin Neuropharmacol; 1984; 7(2):121-33. PubMed ID: 6733692
    [No Abstract]   [Full Text] [Related]  

  • 12. Parcopa: a rapidly dissolving formulation of carbidopa/levodopa.
    Med Lett Drugs Ther; 2005 Jan; 47(1201):12. PubMed ID: 15706700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amantadine and a fixed combination of carbidopa and levodopa in parkinsonism: a preliminary report.
    Savery F
    Curr Ther Res Clin Exp; 1976 Mar; 19(3):337-8. PubMed ID: 817863
    [No Abstract]   [Full Text] [Related]  

  • 14. Clozapine withdrawal symptoms in a Parkinson's disease patient.
    Zesiewicz TA; Borra S; Hauser RA
    Mov Disord; 2002 Nov; 17(6):1365-7. PubMed ID: 12465085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.
    Hauser RA; Koller WC; Hubble JP; Malapira T; Busenbark K; Olanow CW
    Mov Disord; 2000 May; 15(3):485-9. PubMed ID: 10830413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroleptic malignant-like syndrome in an elderly patient caused by abrupt withdrawal of tolcapone, a-catechol-o-methyl transferase inhibitor.
    Iwuagwu CU; Riley D; Bonoma RA
    Am J Med; 2000 Apr; 108(6):517-8. PubMed ID: 10866587
    [No Abstract]   [Full Text] [Related]  

  • 17. Drugs for parkinsonism.
    Med Lett Drugs Ther; 1986 Jun; 28(716):62-4. PubMed ID: 3713639
    [No Abstract]   [Full Text] [Related]  

  • 18. Absorption of orally disintegrating carbidopa-levodopa requires intact small bowel function.
    Iyer SS; Morgan JC; Sethi KD
    Neurology; 2005 Nov; 65(9):1507. PubMed ID: 16275853
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk factors for motor response complications in L-dopa-treated parkinsonian patients.
    Peppe A; Dambrosia JM; Chase TN
    Adv Neurol; 1993; 60():698-702. PubMed ID: 8420213
    [No Abstract]   [Full Text] [Related]  

  • 20. Medical treatment of Parkinson's disease.
    Ahlskog JE
    Compr Ther; 1989 Mar; 15(3):53-9. PubMed ID: 2650977
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.